Answers are grounded in this paper and cite their sources.
mutated ET. In this review, we summarize the clinical features and prognosis of TN-PMF and -ET as well as diagnostic challenges including identification of non-canonical driver mutations. We also discuss additional molecular drivers to better understand possible pathogenic mechanisms underlying triple negative MPNs. Finally, we highlight current therapeutic approaches as well as novel targets, particularly in the difficult to treat TN-PMF population.
No takes yet. Share an insight, caveat, or question.
Tharakan et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: